The Industry Sequenced the Genome. Then It Stopped.
The cost of sequencing a human genome dropped from $3 billion to $200. But sequencing is just the read. The result—turning raw variant data into clinical action—still takes 14 days, costs thousands of dollars, and introduces human error at every step.
That 14-day lag costs lives. In the NICU, it's the difference between intervening and watching. In oncology, it's tumor evolution outpacing treatment. In pharmacogenomics, it's adverse drug reactions that could have been predicted.
NomosLogic closes the gap.
We built the infrastructure layer that transforms genomic data into clinical truth at point-of-care velocity—deterministic, auditable, and hallucination-free.
DIAGNOSTIC LABS
Industrial-Scale Intelligence Metric Value
Reference Asset Vault 13.6 Million
Active Clinical Rules . 1.2 Million
Hardy Bridge Mappings 497,000
Genome Resolution Time 28 Seconds
Multi-Omic Fusion Time 75 Seconds
Evolutionary Simulation Time 130 Seconds
Competitive Time Barrier 5–7 Years
Four Markets. One Infrastructure.
HEALTH SYSTEMS
COVENANT + TRINITY for clinical decision support
• Eliminate the 14-day diagnostic lag in NICU, oncology, and rare disease
• SMART on FHIR integration with Epic and Cerner
• Court-defensible reports with full PMID traceability
• Estimated $10M+ annual savings on manual interpretation
PHARMACIES & PBMs
Real-time prescription interception
• Flag high-risk prescriptions at point of fill
• CYP2D6, CYP2C19, DPYD, SLCO1B1 coverage
• Reduce adverse drug reaction liability
HEALTH PLANS
Population pharmacogenomics and prior authorization
• Stratify covered populations by PGx risk
• Automate prior authorization with genomic evidence
• Reduce hospitalizations from preventable ADRs
PHARMA R&D
PROTEUS for trial design and resistance prediction
• Identify PGx stratification requirements before Phase III
• Predict drug resistance evolution in silico
• Accelerate rare disease cohort discovery by 40–60%
• $10K–$500K per simulation vs. $800M Phase III failure
Sovereign by Design
Patient data never leaves the database. Our Sovereign Stream architecture executes clinical logic inside the PostgreSQL query planner—no data extraction, no application-layer exposure, no attack surface. HIPAA Compliant: Zero-knowledge protocol with salted HMAC-SHA256 SOC 2 Ready: AWS Graviton3/Nitro architecture on private subnets k-Anonymity: Enforced at the SQL layer, not the application layer Audit Trail: Every query cryptographically signed and traceable
Target Discovery Utility:
- Needle-in-a-Haystack Discovery: Traverse 14.3M assets to find the 1-in-a-million multi-gene signatures required for rare disease cohort discovery in seconds.
- The In-Silico Advantage: Dramatically reduce R&D burn by identifying "Fitness Peaks" of therapeutic success through high-velocity genomic modeling.
- Evolutionary Trajectory: Forecast the future of patient biology, identifying risk factors years before clinical manifestation.
We provide the search engine for human biology. Accelerate your recruitment by 40-60% and ensure your drug hits the correct target before the first patient is even enrolled.